SLL
Approved in
relapsed SLL after 2
systemic therapies

ZYDELIG®
Efficacy

ZYDELIG demonstrated powerful, single-agent efficacy in a pivotal phase 2 trial1

ZYDELIG (n=26)

Overall
response rate

ORR*

58%

(95% Cl, 37%-77%)


DURATION
of response

Median DoR

11.9 months

Range=0.0+ to 14.7+ months


TIME
to response

Median time—the first
follow-up, per protocol

1.9
months

Range=1.6 to 8.3 months


Primary endpoint was ORR, as assessed by an IRC. Secondary endpoint was DoR.1

Median duration of exposure to ZYDELIG was 6.1 months.

*Responses were assessed by an IRC using standard criteria for lymphoma.2 Patients were assessed for response at weeks 8, 16, 24, 36, and 48 and every 12 weeks thereafter.

Kaplan-Meier estimate.

CI=confidence interval; CR=complete response; DoR=duration of response; IRC=independent review committee; ORR=overall response rate; PR=partial response; SLL=small lymphocytic lymphoma.